Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2.
Tahmasebi S, Saeed BQ, Temirgalieva E, Yumashev AV, El-Esawi MA, Navashenaq JG, Valizadeh H, Sadeghi A, Aslani S, Yousefi M, Jadidi-Niaragh F, Adigozalou J, Ahmadi M, Roshangar L. Tahmasebi S, et al. Among authors: navashenaq jg. Life Sci. 2021 Jul 1;276:119437. doi: 10.1016/j.lfs.2021.119437. Epub 2021 Mar 28. Life Sci. 2021. PMID: 33789145 Free PMC article.
The role of non-coding genome in the behavior of infiltrated myeloid-derived suppressor cells in tumor microenvironment; a perspective and state-of-the-art in cancer targeted therapy.
Shabgah AG, Salmaninejad A, Thangavelu L, Alexander M, Yumashev AV, Goleij P, Hedayati-Moghadam M, Mohammadi H, Ahmadi M, Navashenaq JG. Shabgah AG, et al. Among authors: navashenaq jg. Prog Biophys Mol Biol. 2021 May;161:17-26. doi: 10.1016/j.pbiomolbio.2020.11.006. Epub 2020 Nov 28. Prog Biophys Mol Biol. 2021. PMID: 33259833 Review.
Immunomodulatory effects of nanocurcumin on Th17 cell responses in mild and severe COVID-19 patients.
Tahmasebi S, El-Esawi MA, Mahmoud ZH, Timoshin A, Valizadeh H, Roshangar L, Varshoch M, Vaez A, Aslani S, Navashenaq JG, Aghebati-Maleki L, Ahmadi M. Tahmasebi S, et al. Among authors: navashenaq jg. J Cell Physiol. 2021 Jul;236(7):5325-5338. doi: 10.1002/jcp.30233. Epub 2020 Dec 28. J Cell Physiol. 2021. Retraction in: J Cell Physiol. 2024 Nov;239(11):e31356. doi: 10.1002/jcp.31356 PMID: 33372280 Retracted.
Combination Cancer Immunotherapy with Dendritic Cell Vaccine and Nanoparticles Loaded with Interleukin-15 and Anti-beta-catenin siRNA Significantly Inhibits Cancer Growth and Induces Anti-Tumor Immune Response.
Kheshti AMS, Hajizadeh F, Barshidi A, Rashidi B, Ebrahimi F, Bahmanpour S, Karpisheh V, Noukabadi FK, Kiani FK, Hassannia H, Atyabi F, Kiaie SH, Kashanchi F, Navashenaq JG, Mohammadi H, Bagherifar R, Jafari R, Zolbanin NM, Jadidi-Niaragh F. Kheshti AMS, et al. Among authors: navashenaq jg. Pharm Res. 2022 Feb;39(2):353-367. doi: 10.1007/s11095-022-03169-2. Epub 2022 Feb 15. Pharm Res. 2022. Retraction in: Pharm Res. 2023 Feb;40(2):615-616. doi: 10.1007/s11095-022-03456-y PMID: 35166995 Retracted.
Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model.
Barshidi A, Karpisheh V, Noukabadi FK, Kiani FK, Mohammadi M, Afsharimanesh N, Ebrahimi F, Kiaie SH, Navashenaq JG, Hojjat-Farsangi M, Zolbanin NM, Mahmoodpoor A, Hassannia H, Nami S, Jalali P, Jafari R, Jadidi-Niaragh F. Barshidi A, et al. Among authors: navashenaq jg. Pharm Res. 2022 Aug;39(8):1851-1866. doi: 10.1007/s11095-022-03297-9. Epub 2022 Jun 17. Pharm Res. 2022. Retraction in: Pharm Res. 2024 Feb;41(2):407-408. doi: 10.1007/s11095-023-03647-1 PMID: 35715669 Retracted.
49 results